data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Replimune Group
(NASDAQ:REPL)
$18.38
0.90[5.15%]
At close: Jul 1
$18.38
00
After Hours: 4:01PM EDT
Day High/Low17.31 - 18.48
52 Week High/Low13.05 - 40.13
Open / Close17.48 / 18.38
Float / Outstanding32M / 49.1M
Vol / Avg.214.3K / 374.6K
Mkt Cap901.9M
P/E-
50d Avg. Price15.83
Div / Yield-
Payout Ratio-
EPS-0.6
Total Float32M

Replimune Group (NASDAQ:REPL), Quotes and News Summary

Replimune Group (NASDAQ: REPL)

Day High/Low17.31 - 18.48
52 Week High/Low13.05 - 40.13
Open / Close17.48 / 18.38
Float / Outstanding32M / 49.1M
Vol / Avg.214.3K / 374.6K
Mkt Cap901.9M
P/E-
50d Avg. Price15.83
Div / Yield-
Payout Ratio-
EPS-0.6
Total Float32M
Benzinga - Jun 23, 2022, 4:26PM
Benzinga - May 26, 2022, 5:17PM
Benzinga - May 24, 2022, 8:33AM
Benzinga - May 20, 2022, 4:29AM
Benzinga - May 19, 2022, 8:02AM
Benzinga - Apr 19, 2022, 12:17PM
Benzinga - Apr 4, 2022, 10:11AM
Benzinga - Mar 18, 2022, 9:12AM
Benzinga - Feb 3, 2022, 8:09AM
Benzinga - Nov 19, 2021, 6:42AM
Benzinga - Nov 4, 2021, 8:19AM
Benzinga - Oct 1, 2021, 8:23AM
Benzinga - Aug 23, 2021, 6:15AM
Benzinga - Aug 9, 2021, 4:47AM
Benzinga - Aug 6, 2021, 8:03AM
Sector: Health Care.Industry: Biotechnology
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Read More

Earnings

see more
Q1 2023Est.ActualSurprise
EPS
(EXPECTED)2022-08-05
REV
Q4 2022Est.ActualSurprise
EPS-0.580-0.600 -0.0200
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Replimune Group Questions & Answers

Q
How do I buy Replimune Group (REPL) stock?
A

You can purchase shares of Replimune Group (NASDAQ: REPL) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Replimune Group's (REPL) competitors?
Q
What is the target price for Replimune Group (REPL) stock?
A

The latest price target for Replimune Group (NASDAQ: REPL) was reported by Wedbush on Tuesday, May 24, 2022. The analyst firm set a price target for 52.00 expecting REPL to rise to within 12 months (a possible 182.92% upside). 7 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Replimune Group (REPL)?
A

The stock price for Replimune Group (NASDAQ: REPL) is $18.38 last updated July 1, 2022, 8:00 PM UTC.

Q
Does Replimune Group (REPL) pay a dividend?
A

There are no upcoming dividends for Replimune Group.

Q
When is Replimune Group (NASDAQ:REPL) reporting earnings?
A

Replimune Group’s Q1 earnings are confirmed for Friday, August 5, 2022.

Q
Is Replimune Group (REPL) going to split?
A

There is no upcoming split for Replimune Group.

Q
What sector and industry does Replimune Group (REPL) operate in?
A

Replimune Group is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.